NIKTIMVO — Total revenues
Incyte NIKTIMVO — Total revenues decreased by 1.7% to $55.09M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 304.7%, from $13.61M to $55.09M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, growing patient adoption, or effective commercial execution for the product. A decrease may signal increased competition, loss of market exclusivity, or declining clinical demand.
Detailed definition
This metric represents the total gross revenue generated from the sale and commercialization of the specific pharmaceuti...
Peer comparison
Comparable to product-specific revenue lines reported by other biopharmaceutical companies, often categorized under 'Product Sales' or 'Net Product Revenue' in segment reporting.
incy_segment_niktimvo_total_revenuesHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $13.61M | $36.15M | $45.83M | $56.04M | $55.09M |
| QoQ Change | — | — | — | — | — | — | — | — | — | +165.6% | +26.8% | +22.3% | -1.7% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | +304.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's niktimvo — total revenues?
- Incyte (INCY) reported niktimvo — total revenues of $55.09M in Q1 2026.
- How has Incyte's niktimvo — total revenues changed year-over-year?
- Incyte's niktimvo — total revenues increased by 304.7% year-over-year, from $13.61M to $55.09M.
- What does niktimvo — total revenues mean?
- The total amount of money earned from sales of the NIKTIMVO drug.